These damages are typically reserved for cases where the defendant, in this case, Novo Nordisk, was grossly negligent or reckless in their actions
On the other hand, you may need a higher dose to increase weight loss results
[15] This signal has not been confirmed in humans, but it is reflected in the prescribing information for approved GLP-1-based medicines such as semaglutide (see the UK Summary of Product Characteristics for Wegovy, available via the electronic Medicines Compendium)
The nocebo effect for biosimilars, where patient-perceived inferiority driven by lower cost reduces reported outcomes, is real and quantifiable
In 2024 alone, prescription fills for FDA-approved weight loss medications Zepbound and Wegovy more than doubled
Ask them to verify the ingredients